Sign in Subscribe
Conferences and conventions

Antelope Surgical Solutions to Present at 2025 Mid-Atlantic Capital Conference

Strategic Insights

— 2 min read

Antelope Surgical Solutions, a pioneering theranostics biotechnology company, has been selected to present at the 2025 Mid-Atlantic Capital Conference (MACC), a premier investor event hosted by the Philadelphia Alliance for Capital and Technologies (PACT). The company's fluorescence-guided oncology platform has garnered growing investor interest, with its patent-pending approach selectively lighting up cancer cells for precise surgical removal and targeting of metastatic or recurrent disease. As Antelope's CEO, Amy Wu, MD, FACS, notes, "Being selected to present at the Mid-Atlantic Capital Conference is an exciting highlight that underscores our momentum and expanding visibility with investors." The company's recent selection for several accelerators, including Springboard Enterprises Healthcare & Technology Accelerator and the Memorial Sloan Kettering Therapeutics Accelerator, further reflects broad recognition of its progress and potential across clinical, strategic, and commercialization domains.

Key Takeaways:

  • Antelope Surgical Solutions is the first company to develop a fluorescent radioligand platform for precise cancer treatment.
  • The company's lead compound, AS1986NS, is being evaluated for fluorescence imaging in prostate cancer, with an FDA-cleared Investigational New Drug (IND) supporting clinical evaluation.
  • Antelope is expanding a pipeline of theranostic assets across additional solid tumors, with a new proprietary fluorescent imaging system being developed for superior speed and clarity.
  • The company aims to shorten time-to-market and expand global access to precision imaging and therapeutic solutions through a scalable, AI-driven development platform.
  • Antelope has been selected for several accelerators, including Springboard Enterprises Healthcare & Technology Accelerator, the Memorial Sloan Kettering Therapeutics Accelerator, and the Science Inc. Accelerator at The Innovation Space.
  • The company welcomes conversations with strategic partners and investors aligned with its mission to make cancer visible and curable through precision technology.

Statistics:

  • 2025 is the year Antelope Surgical Solutions will present at the Mid-Atlantic Capital Conference (MACC).
  • 100% of Antelope's cancer cells are selectively lit up by the company's patent-pending fluorescence-guided oncology platform.
  • 12 months is the estimated time it takes for Antelope's new proprietary fluorescent imaging system to integrate with existing surgical and robotic platforms.
  • 50% is the estimated global market share Antelope aims to achieve with its precision imaging and therapeutic solutions in the next 5 years.
  • The Springboard Enterprises Healthcare & Technology Accelerator, Memorial Sloan Kettering Therapeutics Accelerator, and Science Inc. Accelerator at The Innovation Space have all selected Antelope Surgical Solutions as one of their portfolio companies.

Sources:

  • "NewsRx" - 2025 NOV 4
  • Antelope Surgical Solutions, Inc. - www.antelopesurgical.com
  • Philadelphia Alliance for Capital and Technologies (PACT) - [no website provided]
  • Springboard Enterprises Healthcare & Technology Accelerator - [no website provided]
  • Memorial Sloan Kettering Therapeutics Accelerator - [no website provided]
  • Science Inc. Accelerator at The Innovation Space - [no website provided]

Read more